Agios Pharmaceuticals (NASDAQ:AGIO) Posts Earnings Results, Misses Expectations By $0.04 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04), FiscalAI reports. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $26.39 million.

Here are the key takeaways from Agios Pharmaceuticals’ conference call:

• Mitapivat revenue reached $44.7 million in Q2, including $40.9 million in the U.S., while AQVESME generated 442 cumulative prescriptions from REMS-certified physicians. Payer coverage for U.S. thalassemia patients reached approximately 75%.
• The FDA accepted mitapivat’s sickle cell disease supplemental application for priority review with a November 1, 2026 PDUFA date; Agios is preparing for a potential launch, though the indication is not expected to materially contribute to 2026 revenue.
• Thalassemia launch dynamics are shifting toward a broader non-transfusion-dependent population, which may lengthen treatment initiation to the expected 10–12 weeks. Management will evaluate six-month patient benefit and persistence in the second half and plans to stop reporting REMS prescription counts after Q3 in favor of revenue metrics.
• Agios expanded its rare hematology pipeline by licensing cevidoplenib, a selective oral Syk inhibitor for immune thrombocytopenia, and plans to advance AG-236 into a seamless Phase II/III polycythemia vera program in the second half of 2026.
• The company ended the quarter with approximately $1 billion in cash and marketable securities, but operating expenses increased as commercial investment expanded; full-year operating expenses are expected to remain roughly flat versus 2025 excluding the $25 million cevidoplenib upfront payment.

Agios Pharmaceuticals Stock Down 6.5%

NASDAQ:AGIO opened at $32.75 on Friday. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -4.52 and a beta of 0.54. The company has a fifty day simple moving average of $34.45 and a two-hundred day simple moving average of $30.89.

Institutional Investors Weigh In On Agios Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Wellington Management Group LLP lifted its holdings in Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after buying an additional 2,049,287 shares during the last quarter. MPM Bioimpact LLC purchased a new stake in Agios Pharmaceuticals in the fourth quarter valued at $35,478,000. State Street Corp grew its holdings in shares of Agios Pharmaceuticals by 37.4% during the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after purchasing an additional 845,433 shares during the last quarter. TCG Crossover Management LLC lifted its holdings in shares of Agios Pharmaceuticals by 105.2% in the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after purchasing an additional 733,038 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $19,889,000.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AGIO. HC Wainwright upped their price target on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday. Royal Bank Of Canada increased their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. Bank of America increased their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Finally, Citigroup reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research report on Friday. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of “Hold” and an average price target of $40.38.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Mitapivat revenue surged: Second-quarter worldwide net revenue for PYRUKYND and AQVESME reached $44.7 million, up from $12.5 million a year earlier and well above analyst expectations near $26.4 million. Agios also reported 442 cumulative AQVESME prescriptions in the U.S. as of June 30. Agios second-quarter results and business update
• Positive Sentiment: Important FDA catalyst approaches: The FDA granted Priority Review to mitapivat’s supplemental application in sickle cell disease, with a November 1, 2026 PDUFA target date. Approval could materially expand the drug’s addressable market. Agios projects $45 million to $50 million in 2026 revenue from pyruvate kinase deficiency. Agios revenue outlook and sickle-cell FDA decision
• Positive Sentiment: Analyst remains bullish: HC Wainwright raised its FY2030 EPS estimate to $0.66 from $0.64, maintained a Buy rating, and kept a $55 price target—above the stock’s recent trading level.
• Positive Sentiment: Strong balance sheet and pipeline: Agios held $964.8 million in cash, equivalents, and marketable securities at quarter-end, while adding cevidoplenib for immune thrombocytopenia and advancing AG-236 into Phase 2/3 testing for polycythemia vera. Agios pipeline and financial update
• Neutral Sentiment: Quarterly loss remains significant: Agios reported a second-quarter loss of $1.69 per share, although coverage differed on whether this beat or missed consensus estimates. The loss improved from $1.93 per share a year ago, but the company remains unprofitable.
• Negative Sentiment: Shareholder litigation overhang: Pomerantz LLP announced an investigation into potential claims on behalf of Agios investors, which could create reputational and legal uncertainty. Pomerantz investor investigation

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.